On the contrary, in 2022, the American Heart Association (AHA) together with the American College of Cardiology in guidelines for the management of Heart Failure included the use of SGLT2 inhibitors for the treatment of both HFmrEF and HFpEF. This evidence concerns the gene SLC5A2 and heart failure.